Andrew Denker

1.4k total citations
35 papers, 1.0k citations indexed

About

Andrew Denker is a scholar working on Oncology, Orthopedics and Sports Medicine and Molecular Biology. According to data from OpenAlex, Andrew Denker has authored 35 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Orthopedics and Sports Medicine and 7 papers in Molecular Biology. Recurrent topics in Andrew Denker's work include Bone health and treatments (12 papers), Bone health and osteoporosis research (11 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Andrew Denker is often cited by papers focused on Bone health and treatments (12 papers), Bone health and osteoporosis research (11 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Andrew Denker collaborates with scholars based in United States, Spain and Japan. Andrew Denker's co-authors include Steven B. Nicoll, Rocky S. Tuan, Andrew R. Haas, Scott Moseley, Priya S. Kishnani, Michael P. Whyte, Eric Watsky, Frank Rauch, Elizabeth Rosenberg and Albert Leung and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Kidney International.

In The Last Decade

Andrew Denker

34 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Denker United States	14	415	358	294	283	167	35	1.0k
R.L. van Bezooijen Netherlands	11	767 1.8×	222 0.6×	320 1.1×	254 0.9×	54 0.3×	11	1.3k
Christian Rosenquist Denmark	13	420 1.0×	317 0.9×	496 1.7×	437 1.5×	218 1.3×	17	1.5k
Rebecca R. Miles United States	19	1.1k 2.7×	202 0.6×	799 2.7×	360 1.3×	96 0.6×	30	1.6k
Joseph A. Lorenzo United States	21	906 2.2×	132 0.4×	642 2.2×	264 0.9×	62 0.4×	31	1.4k
P.R. Elford Switzerland	18	678 1.6×	321 0.9×	448 1.5×	136 0.5×	64 0.4×	24	1.2k
Frances L. Swain United States	10	593 1.4×	116 0.3×	322 1.1×	130 0.5×	70 0.4×	11	885
Erik R. Sampson United States	18	704 1.7×	749 2.1×	275 0.9×	78 0.3×	47 0.3×	28	1.5k
Yoshinari Kumagai United States	8	434 1.0×	240 0.7×	637 2.2×	101 0.4×	54 0.3×	8	1.1k
S M D'Souza United States	12	497 1.2×	85 0.2×	758 2.6×	181 0.6×	171 1.0×	15	1.2k
Shibing Yu United States	17	601 1.4×	101 0.3×	275 0.9×	71 0.3×	49 0.3×	25	965

Countries citing papers authored by Andrew Denker

Since Specialization

Citations

This map shows the geographic impact of Andrew Denker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Denker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Denker more than expected).

Fields of papers citing papers by Andrew Denker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Denker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Denker. The network helps show where Andrew Denker may publish in the future.

Co-authorship network of co-authors of Andrew Denker

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Denker. A scholar is included among the top collaborators of Andrew Denker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Denker. Andrew Denker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meißner, D, et al.. (2024). New real‐time PCR test for APOE genotyping in patients with Alzheimer’s disease before anti‐amyloid therapy. Alzheimer s & Dementia. 20(S2). 1 indexed citations

Posner, Marshall R., Deborah Jean Lee Wong, Kevin J. Harrington, et al.. (2024). PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC).. Journal of Clinical Oncology. 42(16_suppl). TPS6113–TPS6113. 1 indexed citations

Saag, Kenneth G., Felicia Cosman, Bente Langdahl, et al.. (2021). Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. Osteoporosis International. 32(9). 1879–1888. 3 indexed citations

Gäckler, Anja, Ulf Schönermarck, Vladimir Dobronravov, et al.. (2021). Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrology. 22(1). 49–49. 21 indexed citations

Ariceta, Gema, Bradley P. Dixon, Seong Heon Kim, et al.. (2020). The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney International. 100(1). 225–237. 58 indexed citations

Seefried, Lothar, Priya S. Kishnani, Scott Moseley, et al.. (2020). Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone. 142. 115664–115664. 30 indexed citations

Kishnani, Priya S., Cheryl R. Greenberg, Frank Rauch, et al.. (2018). Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 121. 149–162. 110 indexed citations

Cosman, Felicia, Nigel Gilchrist, Michael R. McClung, et al.. (2015). A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporosis International. 27(1). 377–386. 19 indexed citations

Simon, James A., Julie Chandler, Keith Gottesdiener, et al.. (2014). Diary of hot flashes reported upon occurrence. Menopause The Journal of The North American Menopause Society. 21(9). 938–944. 15 indexed citations

10.

Stoch, S. Aubrey, David Hreniuk, Chengcheng Liu, et al.. (2013). Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration. International Journal of Clinical Pharmacology and Therapeutics. 51(8). 688–692. 7 indexed citations

11.

C, Liu, et al.. (2013). Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.. PubMed. 20(3). e312–20. 7 indexed citations

12.

Langdahl, Bente, Neil Binkley, Henry G. Bone, et al.. (2012). Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study. Journal of Bone and Mineral Research. 27(11). 2251–2258. 133 indexed citations

13.

Nakhla, Meranda, Andrew Denker, James D. Connor, et al.. (2011). Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children. Clinical Therapeutics. 33(10). 1516–1523. 10 indexed citations

14.

Denker, Andrew, Nicole H. Lazarus, Arturo G. Porras, et al.. (2010). Bioavailability of Alendronate and Vitamin D₃in an Alendronate/Vitamin D₃Combination Tablet. The Journal of Clinical Pharmacology. 51(10). 1439–1448. 15 indexed citations

15.

Boot, J. D., Sanne Lysbet de Haas, Joop van Gerven, et al.. (2008). MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulmonary Pharmacology & Therapeutics. 21(3). 573–577. 8 indexed citations

16.

Lasseter, Kenneth C., et al.. (2005). Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates. Clinical Drug Investigation. 25(2). 107–114. 40 indexed citations

17.

Ward, Leanne M., Andrew Denker, Arturo G. Porras, et al.. (2005). Single-Dose Pharmacokinetics and Tolerability of Alendronate 35- and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I. The Journal of Clinical Endocrinology & Metabolism. 90(7). 4051–4056. 47 indexed citations

18.

Denker, Andrew, Andrew R. Haas, Steven B. Nicoll, & Rocky S. Tuan. (1999). Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures. Differentiation. 64(2). 67–76. 209 indexed citations

19.

Nicoll, Steven B., Andrew Denker, & R.S. Tuan. (1995). In Vitro Characterization of Transforming Growth Factor-ß1-Loaded Composites of Biodegradable Polymer and Mesenchymal Cells. Digital Commons - USU (Utah State University). 5(3). 1. 3 indexed citations

20.

Denker, Andrew, Steven B. Nicoll, & Rocky S. Tuan. (1995). Formation of cartilage-like spheroids by micromass cultures of murine C3H10T1/2 cells upon treatment with transforming growth factor-β1. Differentiation. 59(1). 25–34. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact